CLINIAL Inc. (Shibuya-ku, Tokyo; CEO: Takaaki Mizuno) has completed a seed round raising a total of 75 million yen, through J-KISS convertible equity with existing investor Greencore Inc. as the lead subscriber, with the aim of expanding its business and accelerating research and development. This round marks CLINIAL’s first full-scale growth investment round.
The funds raised will be allocated primarily to the following areas:
- Enhancing existing features and developing new features for our standardized healthcare-data foundation and products specialized for oncology
- Advancing joint and clinical research with medical institutions including the National Cancer Center Japan and the Chiba Cancer Center
- Product rollout and validation toward collaboration with cancer-specialty institutions in Japan and abroad
- Product rollout for medical institutions and pharmaceutical companies, and further strengthening of quality, security, and regulatory compliance
As a startup providing “data-utilization infrastructure for cancer care,” CLINIAL has been building the foundations to put data generated in clinical and research settings to use for treatment selection, drug discovery, and clinical research. Through this fundraising, we will collaborate even more closely with cancer-care and research settings and contribute to delivering care that is valuable to each individual patient.